ABVC BioPharma (ABVC) Competitors

$1.07 -0.02 (-1.83%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$1.07 0.00 (0.00%)

As of 03:59 AM Eastern

ABVC vs. CYPH, CUE, CGTX, KALA, and ONCY

Should you buy ABVC BioPharma stock or one of its competitors? MarketBeat compares ABVC BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ABVC BioPharma include Cypherpunk Technologies (CYPH), Cue Biopharma (CUE), Cognition Therapeutics (CGTX), KALA BIO (KALA), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does ABVC BioPharma compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Cypherpunk Technologies had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Cypherpunk Technologies and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.08 beat Cypherpunk Technologies' score of -0.30 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cypherpunk Technologies has higher earnings, but lower revenue than ABVC BioPharma. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
ABVC BioPharma	$510K	53.37	-$7.91M	-$0.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cypherpunk Technologies' return on equity of -48.33% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
ABVC BioPharma	N/A	-65.11%	-40.13%

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cypherpunk Technologies has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

ABVC BioPharma beats Cypherpunk Technologies on 6 of the 11 factors compared between the two stocks.

How does ABVC BioPharma compare to Cue Biopharma?

ABVC BioPharma (NASDAQ:ABVC) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

ABVC BioPharma has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 1.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ABVC BioPharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. ABVC BioPharma's return on equity of -65.11% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-65.11%	-40.13%
Cue Biopharma	-59.65%	-98.30%	-53.69%

ABVC BioPharma has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	53.37	-$7.91M	-$0.40	N/A
Cue Biopharma	$27.47M	3.15	-$26.60M	-$5.58	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cue Biopharma had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Cue Biopharma and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.08 beat Cue Biopharma's score of 1.08 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ABVC BioPharma beats Cue Biopharma on 9 of the 13 factors compared between the two stocks.

How does ABVC BioPharma compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Cognition Therapeutics had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 6 mentions for Cognition Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.08 beat Cognition Therapeutics' score of 0.61 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 205.81%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
ABVC BioPharma	$510K	53.37	-$7.91M	-$0.40	N/A

ABVC BioPharma's return on equity of -65.11% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
ABVC BioPharma	N/A	-65.11%	-40.13%

43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 14.4% of Cognition Therapeutics shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cognition Therapeutics and ABVC BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

KALA BIO currently has a consensus price target of $1,018.75, suggesting a potential upside of 37,492.25%. Given KALA BIO's stronger consensus rating and higher possible upside, research analysts clearly believe KALA BIO is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, KALA BIO had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for ABVC BioPharma. KALA BIO's average media sentiment score of 1.38 beat ABVC BioPharma's score of 1.08 indicating that KALA BIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ABVC BioPharma has higher revenue and earnings than KALA BIO. ABVC BioPharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
ABVC BioPharma	$510K	53.37	-$7.91M	-$0.40	N/A

KALA BIO has a beta of -2.23, meaning that its share price is 323% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

ABVC BioPharma's return on equity of -65.11% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-12,971.16%	-83.56%
ABVC BioPharma	N/A	-65.11%	-40.13%

Summary

KALA BIO and ABVC BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ABVC BioPharma's return on equity of -65.11% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-14,442.84%	-300.87%
ABVC BioPharma	N/A	-65.11%	-40.13%

Oncolytics Biotech has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Oncolytics Biotech presently has a consensus target price of $8.50, suggesting a potential upside of 962.37%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than Oncolytics Biotech. ABVC BioPharma is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
ABVC BioPharma	$510K	53.37	-$7.91M	-$0.40	N/A

In the previous week, Oncolytics Biotech and Oncolytics Biotech both had 2 articles in the media. ABVC BioPharma's average media sentiment score of 1.08 beat Oncolytics Biotech's score of -0.36 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oncolytics Biotech and ABVC BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.73M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-2.68	18.13	20.86	25.23
Price / Sales	53.37	275.82	552.57	80.03
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.06	6.57	9.67	6.63
Net Income	-$7.91M	$24.35M	$3.56B	$335.59M
7 Day Performance	1.90%	-2.53%	-1.67%	-1.20%
1 Month Performance	-18.94%	-3.55%	-2.63%	-1.16%
1 Year Performance	-22.46%	53.51%	30.05%	28.10%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	1.2775 of 5 stars	$1.07 -1.8%	N/A	-27.7%	$27.73M	$510K	N/A	30	Positive News Earnings Report
CYPH Cypherpunk Technologies	0.4453 of 5 stars	$1.13 +5.6%	N/A	+159.4%	$110.38M	N/A	16.14	40	Earnings Report Analyst Downgrade High Trading Volume
CUE Cue Biopharma	0.8146 of 5 stars	$33.98 -2.7%	N/A	-96.7%	$110.10M	$27.47M	N/A	60	Positive News Earnings Report Analyst Downgrade
CGTX Cognition Therapeutics	3.186 of 5 stars	$1.23 -0.8%	$3.33 +171.0%	+235.2%	$109.90M	N/A	N/A	20
KALA KALA BIO	2.7202 of 5 stars	$0.12 +2.7%	$20.38 +17,602.0%	-98.5%	$106.98M	N/A	N/A	30	Positive News Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. CYPH, CUE, CGTX, KALA, and ONCY

How does ABVC BioPharma compare to Cypherpunk Technologies?

Summary

How does ABVC BioPharma compare to Cue Biopharma?

Summary

How does ABVC BioPharma compare to Cognition Therapeutics?

Summary

How does ABVC BioPharma compare to KALA BIO?

Summary

How does ABVC BioPharma compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. CYPH, CUE, CGTX, KALA, and ONCY

How does ABVC BioPharma compare to Cypherpunk Technologies?

Does the media favor CYPH or ABVC?

Which has stronger valuation and earnings, CYPH or ABVC?

Do analysts prefer CYPH or ABVC?

Is CYPH or ABVC more profitable?

Do institutionals and insiders have more ownership in CYPH or ABVC?

Which has more volatility and risk, CYPH or ABVC?

Summary

How does ABVC BioPharma compare to Cue Biopharma?

Which has more risk and volatility, ABVC or CUE?

Do institutionals and insiders believe in ABVC or CUE?

Is ABVC or CUE more profitable?

Which has better valuation & earnings, ABVC or CUE?

Do analysts prefer ABVC or CUE?

Does the media prefer ABVC or CUE?

Summary

How does ABVC BioPharma compare to Cognition Therapeutics?

Does the media refer more to CGTX or ABVC?

Which has more volatility and risk, CGTX or ABVC?

Do analysts rate CGTX or ABVC?

Which has stronger earnings and valuation, CGTX or ABVC?

Is CGTX or ABVC more profitable?

Do insiders and institutionals have more ownership in CGTX or ABVC?

Summary

How does ABVC BioPharma compare to KALA BIO?

Do analysts recommend KALA or ABVC?

Does the media favor KALA or ABVC?

Do institutionals & insiders hold more shares of KALA or ABVC?

Which has preferable valuation and earnings, KALA or ABVC?

Which has more risk and volatility, KALA or ABVC?

Is KALA or ABVC more profitable?

Summary

How does ABVC BioPharma compare to Oncolytics Biotech?

Do insiders & institutionals hold more shares of ONCY or ABVC?

Is ONCY or ABVC more profitable?

Which has more volatility and risk, ONCY or ABVC?

Do analysts recommend ONCY or ABVC?

Which has stronger earnings & valuation, ONCY or ABVC?

Does the media favor ONCY or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools